Breaking Finance News

Deutsche Bank reiterated BTG PLC (LON:BTG) to Buy in a statement released earlier today.

Deutsche Bank has reiterated BTG PLC (LON:BTG) to Buy in a report released on Friday October 07, 2016. They are also indicating a possible upside of 0%.

On 10/06/2016, Stifel released a statement about BTG PLC (LON:BTG) held steady the target price at 640.00GBX that suggested a downside of -0.06%.

Yesterday BTG PLC (LON:BTG) traded 3.63% higher at 0.00GBX. The company’s 50-day moving average is 627.97GBX and its 200-day moving average is 640.80GBX. The last stock close price is down 10.62% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Volume of trade was down over the average, with 355,500 shares of BTG changing hands under the typical 588,749

Recent Performance Chart


BTG PLC has 52 week low of 504.00GBX and a 52 week high of 739.50GBX with a PE ratio of 45.44 and has a market capitalization of 0 GBX.

General Company Details For BTG PLC (LON:BTG)

BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing. The Interventional Medicine segment includes oncology, vascular and pulmonology. The segment's products include Beads, TheraSphere, EkoSonic, Varithena and PneumRx Coils for use in the treatment of liver tumors, blood clots, varicose veins and advanced emphysema. The Specialty Pharmaceuticals segment includes CroFab, DigiFab, Voraxaze and Vistogard products for use in the treatment of crotalid envenomation, digoxin toxicity, high-dose methotrexate toxicity and 5-fluorouracil toxicity. The Licensing segment includes Zytiga, Two-Part Hip Cup and Lemtrada products for use in the treatment of advanced prostate cancer, hip replacement and multiple sclerosis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.